Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00661_DB00872_nanopub.RAAo1gtkD4hvo_eOPxPk6ECsh1xFvc-cm6DrVLxj7GN_4#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00661_DB00872 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00661_DB00872 label "DDI between Verapamil and Conivaptan - Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed. [drugbank_resource:DB00661_DB00872]" assertion.
- drugbank_resource:DB00661_DB00872 identifier "drugbank_resource:DB00661_DB00872" assertion.
- drugbank_resource:DB00661_DB00872 title "DDI between Verapamil and Conivaptan - Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed." assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB00872 assertion.
- drugbank:DB00872 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB00872 assertion.